Published in Mediators Inflamm on September 14, 2010
MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway. Mol Biol Cell (2012) 1.14
Toll-like receptors and cancer, particularly oral squamous cell carcinoma. Front Immunol (2014) 0.99
Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression. J Gastroenterol (2013) 0.92
The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol Immunother (2011) 0.90
Immune response in thyroid cancer: widening the boundaries. Scientifica (Cairo) (2014) 0.84
Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol (2012) 0.81
Curcumin modulates TLR4/NF-κB inflammatory signaling pathway following traumatic spinal cord injury in rats. J Spinal Cord Med (2014) 0.78
Microbiome, innate immunity, and esophageal adenocarcinoma. Clin Lab Med (2014) 0.78
Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants. Oxid Med Cell Longev (2016) 0.77
Expression of Toll-like receptor 4 in ovarian serous adenocarcinoma and correlation with clinical stage and pathological grade. Int J Clin Exp Med (2015) 0.77
The nucleic acid scavenger polyamidoamine third-generation dendrimer inhibits fibroblast activation and granulation tissue contraction. Plast Reconstr Surg (2014) 0.76
Gonadotropin-mediated chemoresistance: Delineation of molecular pathways and targets. BMC Cancer (2015) 0.75
Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling. J Immunol Res (2016) 0.75
From Inflammation to Current and Alternative Therapies Involved in Wound Healing. Int J Inflam (2017) 0.75
Effects of cord blood vitamin D levels on the risk of neonatal sepsis in premature infants. Korean J Pediatr (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
Innate immune recognition. Annu Rev Immunol (2001) 26.65
Toll-like receptors. Annu Rev Immunol (2001) 26.06
NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A (2006) 21.58
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 13.79
MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A (2007) 11.42
TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med (2007) 9.77
Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med (2005) 8.49
Toll-like receptors control activation of adaptive immune responses. Nat Immunol (2001) 7.54
The interleukin-8 pathway in cancer. Clin Cancer Res (2008) 7.12
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Regulation of phagosome maturation by signals from toll-like receptors. Science (2004) 6.79
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science (2007) 5.54
Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem (2007) 4.56
Physiological and molecular mechanisms of lymphocyte homing. Annu Rev Immunol (1992) 4.50
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer (2005) 3.72
Endogenous ligands of Toll-like receptors. J Leukoc Biol (2004) 3.53
Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology (2003) 3.51
Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med (2002) 3.47
Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest (1990) 3.39
Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation (2004) 3.38
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res (2006) 3.21
TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A (2004) 3.04
Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91
Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol (2007) 2.89
TLR3 can directly trigger apoptosis in human cancer cells. J Immunol (2006) 2.79
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol (2003) 2.08
IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J Immunol (2004) 1.99
The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity. J Exp Med (1978) 1.96
TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol (2007) 1.72
NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol (2004) 1.71
Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene (2008) 1.69
How microorganisms tip the balance between interleukin-12 family members. Nat Rev Immunol (2008) 1.65
Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res (2007) 1.53
Tumor necrosis factor alpha, but not Fas, mediates hepatocellular apoptosis in the murine ischemic liver. Gastroenterology (2002) 1.42
Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. Am J Pathol (2007) 1.32
Toll-like receptors, inflammation and cancer. Semin Cancer Biol (2005) 1.29
Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. J Leukoc Biol (2006) 1.27
Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer (2008) 1.25
Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci (2007) 1.23
Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol (2007) 1.21
Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun (2006) 1.20
Heterogeneity of TLR-induced responses in dendritic cells: from innate to adaptive immunity. Immunobiology (2004) 1.18
Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin Genet (2006) 1.18
Ras participates in the activation of p38 MAPK by interleukin-1 by associating with IRAK, IRAK2, TRAF6, and TAK-1. J Biol Chem (2001) 1.16
Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother (2008) 1.15
Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol (2005) 1.08
Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid. Lab Invest (2006) 1.04
Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst (2003) 1.02
Increase in immune cell infiltration with progression of oral epithelium from hyperkeratosis to dysplasia and carcinoma. Br J Cancer (2002) 1.01
Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin Cancer Res (2008) 1.01
Dendritic cells as vectors for immunotherapy of cancer. Semin Cancer Biol (2003) 0.95
Induction of TLR2 expression by inflammatory stimuli is required for endothelial cell responses to lipopeptides. Mol Immunol (2008) 0.95
Ligation of TLR2 by versican: a link between inflammation and metastasis. Arch Med Res (2009) 0.95
Toll to be paid at the gateway to the vessel wall. Arterioscler Thromb Vasc Biol (2005) 0.91
Sequence variants in toll-like receptor 10 are associated with nasopharyngeal carcinoma risk. Cancer Epidemiol Biomarkers Prev (2006) 0.90
Modulation of regulatory T cells in health and disease: role of toll-like receptors. Inflamm Allergy Drug Targets (2009) 0.86
The NF-kappaB signalling pathway is involved in the LPS/IL-2-induced upregulation of FoxP3 expression in human CD4+CD25high regulatory T cells. Exp Dermatol (2009) 0.85
[Induction of apoptosis in human head and neck cancer cell lines by an active component of OK-432 through p53-independent pathway via toll-like receptor (TLR) 4 signaling]. Gan To Kagaku Ryoho (2005) 0.78
The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med (2005) 3.26
A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia. Eur J Epidemiol (2006) 1.68
Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol (2010) 1.47
Hypereosinophilic syndrome: another face of janus? Leuk Res (2008) 1.47
Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol (2012) 1.41
Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) (2009) 1.17
Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin Cancer Res (2007) 1.16
Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res (2008) 1.03
Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther (2008) 1.02
A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly. Clin Ther (2011) 0.96
Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol (2007) 0.91
Malignant lymphoma in primary Sjögren's syndrome: an update on the pathogenesis and treatment. Semin Arthritis Rheum (2013) 0.88
The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic estimates. BMC Musculoskelet Disord (2012) 0.87
Myelodysplasia and autoimmunity. Curr Opin Rheumatol (2012) 0.86
Aplastic anemia associated with interferon alpha 2a in a patient with chronic hepatitis C virus infection: a case report. J Med Case Rep (2010) 0.84
MDR1 mRNA expression and MDR1 gene variants as predictors of response to chemotherapy in patients with acute myeloid leukaemia: a meta-analysis. Biomarkers (2013) 0.83
Variants of the MTHFR gene and susceptibility to acute lymphoblastic leukemia in children: a synthesis of genetic association studies. Cancer Epidemiol (2011) 0.82
The role of MTHFR gene in multiple myeloma. J Hum Genet (2008) 0.81
Multiple autoimmune phenomena in splenic marginal zone lymphoma. Leuk Lymphoma (2006) 0.81
No evidence for increased prevalence of JAK2 V617F in women with a history of recurrent miscarriage. Br J Haematol (2008) 0.80
Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res (2006) 0.80
Aberrant alternative splicing of interferon regulatory factor-1 (IRF-1) in myelodysplastic hematopoietic progenitor cells. Leuk Res (2006) 0.80
GSTT1 and GSTM1 polymorphisms and myelodysplastic syndrome risk: a systematic review and meta-analysis. Int J Cancer (2010) 0.80
Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics. Medicine (Baltimore) (2007) 0.79
Routine application of a novel MLPA-based first-line screening test uncovers clinically relevant copy number aberrations in haematological malignancies undetectable by conventional cytogenetics. Hematology (2013) 0.79
The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies. Leuk Lymphoma (2012) 0.79
RNA interference of interferon regulatory factor-1 gene expression in THP-1 cell line leads to Toll-like receptor-4 overexpression/activation as well as up-modulation of annexin-II. Neoplasia (2007) 0.78
GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes. Am J Hematol (2007) 0.77
Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: a meta-analysis of randomized controlled trials. Clin Ther (2010) 0.77
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. Am J Hematol (2011) 0.77
Myelofibrosis-associated massive splenomegaly: a cause of increased intra-abdominal pressure, pulmonary hypertension, and positional dyspnea. Am J Hematol (2005) 0.76
FDG-PET for detecting local tumor recurrence of ablated liver metastases: a diagnostic meta-analysis. Biomarkers (2012) 0.76
Indications for bone marrow examination in autoimmune disorders with concurrent haematologic alterations. Clin Exp Rheumatol (2012) 0.76
A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases. Expert Rev Clin Immunol (2014) 0.75
Inheritance and Myelodysplasia progression. Leuk Res (2013) 0.75
Bone marrow necrosis in sickle cell anaemia. Blood Transfus (2010) 0.75
Monoclonal antibodies in rare acquired thrombotic disorders: the paradigms of paroxysmal nocturnal hemoglobinuria, thrombotic thrombocytopenic purpura and central retinal vein occlusion. Curr Vasc Pharmacol (2010) 0.75
Translocation (6;13)(p21;q14.1) as a rare nonrandom cytogenetic abnormality in chronic lymphocytic leukemia. Cancer Genet Cytogenet (2010) 0.75
Cladribine therapy in adults with advanced Langerhans cell histiocytosis. Leuk Lymphoma (2012) 0.75
Prognostication of the high-risk WM patient. Clin Lymphoma Myeloma Leuk (2011) 0.75
Stroke in paroxysmal nocturnal haemoglobinuria: patterns of disease and outcome. Thromb Haemost (2007) 0.75
Membranoproliferative glomerulonephritis in the setting of multicentric angiofollicular lymph node hyperplasia (Castleman's disease) complicated by Evan's syndrome. J Clin Pathol (2010) 0.75
Predicting progression to lymphoma in Sjögren's syndrome patients. Expert Rev Clin Immunol (2014) 0.75
Bone marrow necrosis and fat embolism syndrome presented as conus medullaris syndrome in a patient with primary mediastinal large B-cell lymphoma. Leuk Res (2009) 0.75
B-cell chronic lymphocytic leukaemia presenting as lower motor neuron disease and SS. Rheumatology (Oxford) (2012) 0.75